Encephalitis Treatment Market Report 2026

The encephalitis treatment market size has grown strongly in recent years. It will grow from $22.17 billion in 2025 to $23.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to viral infection outbreaks, neurological disorder awareness, hospital icu expansion, diagnostic imaging availability, emergency neurology care.

The encephalitis treatment market size is expected to see strong growth in the next few years. It will grow to $29.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to immunotherapy advancements, rapid diagnostic adoption, intensive care investments, aging population vulnerability, neurological research funding. Major trends in the forecast period include rising incidence of viral and autoimmune encephalitis, increased use of targeted antiviral therapies, growing demand for early neurological diagnosis, expansion of intensive care treatment protocols, focus on reducing neurological complications.

The increasing investment in healthcare infrastructure is expected to drive the growth of the encephalitis treatment market in the coming years. Healthcare infrastructure includes hospitals, clinics, laboratories, and medical resources equipped with advanced technologies and supported by trained healthcare professionals to deliver essential medical services. The rise in healthcare infrastructure spending is driven by the need to strengthen diagnostic capabilities, expand critical care capacity, and improve access to specialized neurological services. Effective encephalitis treatment depends on robust healthcare infrastructure, as patients require prompt diagnosis, advanced imaging, administration of antiviral or immunotherapy treatments, and comprehensive supportive care in well-equipped medical facilities. For example, in May 2024, according to the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, rising investment in healthcare infrastructure is fueling the growth of the encephalitis treatment market.

Major companies operating in the encephalitis treatment market are prioritizing strategic investments to speed up the development of innovative therapies, strengthen research and development capabilities, and broaden clinical trial activities. For instance, in September 2023, Arialys Therapeutics, a US-based preclinical-stage company, secured $58 million in seed funding to advance its lead candidate, ART5803, intended to treat anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis. The company plans to begin clinical trials in healthy volunteers by late 2024, followed by studies in ANRE patients in early 2025. Arialys is focused on developing precision therapies that directly target pathogenic antibodies affecting the central nervous system.

In March 2023, UC Davis Health, a US-based academic health institution, partnered with Propeller Health to provide personalized treatment for chronic obstructive pulmonary disease and asthma through remote patient monitoring technology. Through this collaboration, UC Davis Health offers eligible patients access to Propeller Health’s remote patient monitoring services, which deliver individualized therapy for high-risk COPD and asthma using sensors, a smartphone application, and a web-based platform. Propeller Health is a US-based mobile health company that supplies sensors, mobile applications, analytics, and related services to support respiratory health management.

Major companies operating in the encephalitis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Aurobindo Pharma Limited, Hikma Pharmaceuticals plc, Vir Biotechnology, Torrent Pharmaceuticals Ltd., Valneva SE, Sangamo Therapeutics, Xenon Pharmaceuticals, Tiziana Life Sciences, Vivet Therapeutics, Tetraphase Pharmaceuticals, QED Therapeutics.

North America was the largest region in the encephalitis treatment market in 2025. The regions covered in the encephalitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the encephalitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the encephalitis treatment market by increasing costs of imported antiviral drugs, immunotherapies, and diagnostic equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported treatments. These tariffs raise therapy costs by increasing medication pricing and diagnostic expenses, potentially delaying timely intervention in acute cases. However, they promote domestic pharmaceutical production, supporting local manufacturing of antivirals and immunotherapies.

The encephalitis treatment market research report is one of a series of new reports that provides encephalitis treatment market statistics, including encephalitis treatment industry global market size, regional shares, competitors with a encephalitis treatment market share, detailed encephalitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the encephalitis treatment industry. This encephalitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Encephalitis treatment involves managing a medical condition characterized by inflammation of the brain, most commonly caused by viral infections, fungal infections, autoimmune reactions, or certain medications. The purpose of encephalitis treatment is to control symptoms, slow disease progression, and prevent potential complications.

The main disease types included in encephalitis treatment are primary encephalitis and secondary encephalitis. Primary encephalitis refers to inflammation that begins directly in the brain rather than resulting from an infection elsewhere in the body. Treatment for primary encephalitis includes antiviral medications, supportive care, and symptom management. The treatment options consist of antiviral agents, steroid injections, antibiotics, immunoglobulin therapy, plasmapheresis, and other therapies, which are administered through routes such as oral, parenteral, and other methods. Diagnostic tests include imaging tests, blood tests, biopsies, and other diagnostic procedures, and these treatments are used by end users such as hospitals, specialty clinics, and others.

The encephalitis treatment market consists of revenues earned by entities by providing plasmapheresis, immunoglobulin therapy, computed tomography (CT scans), magnetic resonance imaging (MRI) and magnetoencephalography (MEG) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalitis treatment market also includes sales of immunosuppressant drugs, antiseizure medicines and immunomodulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.